Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.